2018-03-22 | 태준
Taejoon Pharmaceutical Co., Ltd. ("Taejoon") held an annual kick-off
meeting and new CI (Corporate Identity) proclamation ceremony at its
headquarter in Hannam-dong, Seoul on January 2, 2017.
Taejoon
Pharmaceutical's New Corporate Identity wordmark symbolizes, Taejoon's
direction to go closer to customer with a image of reminiscent of smile.
In this event, the introduction of new CI and the badge presentations
to employees were done to emphasize unity of company.
Established
in 1978, Taejoon is currently exporting the ophthalmic medicinal
products manufactured at its EU-GMP approved facility which was the
first EU-GMP approved manufacturing facility in Korea to many countries
including the U.S., Europe and China. It is also the world’s first
contrast media specialized pharmaceutical company which has the
technical skills in all three fields of vascular, MRI, and
gastrointestinal contrast media.
In 2012, Taejoon was selected
as ‘Innovative Pharmaceutical Company’ and recertified in 2015 based on
the capability in novel drug development activities and the overseas
market expansion.